Dr Brett Stringer BMedSc MBBS PhD

Brain Cancer Research Fellow

Flinders Health and Medical Research Institute (FHMRI)

College of Medicine & Public Health

Flinders University

Sturt Road

Bedford Park South Australia 5042

GPO Box 2100 Adelaide SA 5001

M: +61 491 077 863

E: brett.stringer@flinders.edu.au

W: https://www.flinders.edu.au/people/brett.stringer

Dr Brett Stringer is the Brain Cancer Research Fellow at Flinders University. He has co-authored more than 50 original research reports, mostly on brain cancer. His achievements include the co-establishment of a brain tumour biobank and a widely shared, extensively characterised, collection of brain cancer cell lines (Q-Cell), in addition to work that helped lead to the clinical trial of a new therapy (Ifabotuzumab) for glioblastoma. The goal of his current research is to identify novel pharmacologically amenable ways to treat malignant brain tumours by identifying dependencies created by the tumour microenvironment as well as by the genetic events that lead to the development of brain tumours. He contributes to research projects in the laboratories of Assoc Prof Simon Conn and Assoc Prof Cedric Bardy, at Flinders University and the South Australian Health and Medical Research Institute (SAHMRI), respectively.

Current research projects investigate:

The effect of cerebrospinal fluid on the phenotype of brain cancer.

The role of circular RNA in brain cancer.

The transcriptomic changes that underlie the development of brain cancer.

2021 Research Funded:

Modelling brain cancer to improve treatment for brain cancer

Funding: $43,000

Project: In the most devastating form of brain cancer – glioblastoma – the same few regions of our DNA are commonly mutated. However, despite the low number of these commonly occurring mutations, we know very little about how this actually causes cancer, or how it can help us treat brain cancer more effectively.

By replicating these common genetic mutations in normal brain cells, we have, for the first time, created unique models of brain cancer that represent each major subtype of known glioblastomas. We will characterise these at the finest possible resolution, down to single cells, to understand how brain cancers arise and how we might better intervene to treat them.